Pfizer's Legacy Wyeth Consumer Products Help Diversified Businesses Grow
This article was originally published in The Tan Sheet
Revenue from legacy Wyeth products, including Advil pain reliever and Centrum multivitamins, was a bright spot for Pfizer in its third quarter, which was marked by a decline in profit due to costs of the acquisition.
You may also be interested in...
Capsugel likely will be the first divestiture from Pfizer's Diversified Businesses following the 2009 Wyeth merger and reorganization, and could be a prime target for a private equity acquisition
Pfizer plans to give its consumer products businesses "the opportunity to grow" as it integrates Wyeth into its operations, according to CEO Jeffrey Kindler
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.